Several other research firms also recently issued reports on CTLT. Bank of America Corp restated a “buy” rating and set a $37.00 price objective (up previously from $32.00) on shares of Catalent in a report on Wednesday. William Blair upgraded Catalent from a “market perform” rating to an “outperform” rating in a report on Monday. Zacks Investment Research downgraded Catalent from a “buy” rating to a “sell” rating in a report on Tuesday, May 9th. TheStreet upgraded Catalent from a “d+” rating to a “c” rating in a report on Monday, February 6th. Finally, Jefferies Group LLC boosted their price objective on Catalent from $29.00 to $32.00 and gave the stock a “hold” rating in a report on Monday, February 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. Catalent presently has a consensus rating of “Buy” and an average price target of $30.71. Shares of Catalent (NASDAQ:CTLT) traded down 1.678% during mid-day trading on Tuesday, reaching $33.685. 682,572 shares of the company’s stock traded hands. Catalent has a 12 month low of $20.94 and a 12 month high of $34.81. The stock has a market cap of $4.21 billion and a PE ratio of 39.676. The firm has a 50 day moving average price of $29.37 and a 200-day moving average price of $27.35.
Catalent Inc (NASDAQ:CTLT) – Equities researchers at KeyCorp boosted their FY2019 EPS estimates for shares of Catalent in a research note issued to investors on Sunday. KeyCorp analyst M. Mishan now forecasts that the company will post earnings of $1.68 per share for the year, up from their prior forecast of $1.65.
A number of institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. boosted its position in Catalent by 15.5% in the first quarter. Macquarie Group Ltd. now owns 1,115,335 shares of the company’s stock valued at $31,586,000 after buying an additional 149,564 shares during the period. Gareth Morgan Investments Limited Partnership acquired a new position in Catalent during the first quarter valued at $1,925,000. Tudor Investment Corp ET AL boosted its position in Catalent by 29.8% in the first quarter. Tudor Investment Corp ET AL now owns 17,521 shares of the company’s stock valued at $496,000 after buying an additional 4,021 shares during the period. Redmile Group LLC acquired a new position in Catalent during the first quarter valued at $17,672,000. Finally, Endurant Capital Management LP boosted its position in Catalent by 393.7% in the first quarter. Endurant Capital Management LP now owns 291,308 shares of the company’s stock valued at $8,250,000 after buying an additional 232,300 shares during the period. In other Catalent news, insider John R. Chiminski sold 73,819 shares of Catalent stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $28.62, for a total transaction of $2,112,699.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Sharon Johnson sold 9,160 shares of Catalent stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $29.00, for a total value of $265,640.00. The disclosure for this sale can be found here.
Catalent Company Profile Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent Inc and related companies with our FREE daily email newsletter.